Literature DB >> 32980

A study of the relationship between cardiac beta-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines.

A Bilski, H H Robertson, J L Wale.   

Abstract

1. The intrinsic sympathomimetic activity of a range of beta-adrenoceptor antagonists and its relationship to beta-adrenoceptor blockade was studied in pentobarbitone-anaesthetized, vagotomized rats which had been depleted of catecholamines by pretreatment with syrosingopine. Dichlorisoprenaline, practolol, oxprenolol, pindolol and acebutolol, produced dose-dependent positive chronotropic responses in this preparation. 2. The relationship between the dose requirements for this intrinsic sympathomimetic activity and beta-adrenoceptor-blocking activity was not the same for all drugs: (i) dichlorisoprenaline and practolol had intrinsic activity at all beta-adrenoceptor-blocking doses; and (ii) oxprenolol, pindolol and acebutolol had predominantly beta-adrenoceptor blockade at the lower dose levels and agonist activity only became significant at high doses relative to those producing beta-adrenoceptor blockade. 3. The positive chronotropic response to both practolol and pindolol was observed in rats which had been pithed and was antagonized by propranolol (0.1-3.0 mg/kg, i.v.), indicating that beta-adrenoceptors were involved. 4. It was concluded that the intrinsic sympathomimetic activity of beta-adrenoceptor antagonists was not a simple property as it was described by the relationship between the dose requirements for intrinsic sympathomimetic activity and for beta-adrenoceptor blockade as well as the degree of partial agonist activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 32980     DOI: 10.1111/j.1440-1681.1979.tb00001.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  11 in total

1.  Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant?

Authors:  D G McDevitt
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

2.  Pharmacology of celiprolol.

Authors:  W J Louis; O H Drummer; L H Tung
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

3.  The cardiovascular acitivity of ICI 118,587 a novel beta-adrenoceptor partial agonist [proceedings].

Authors:  J J Barlow; B D Main; J A Moors; A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

4.  Proceedings of the British Pharmacological Society. 17th-19th December, 1979: University of London (Institute of Education).

Authors: 
Journal:  Br J Pharmacol       Date:  1980-06       Impact factor: 8.739

Review 5.  Pindolol--the pharmacology of a partial agonist.

Authors:  B J Clark; K Menninger; A Bertholet
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors:  A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

7.  Effects of beta-adrenoceptor blockade on heart rate and physiological tremor in diabetics with autonomic neuropathy. A comparative study of epanolol, atenolol and pindolol.

Authors:  W Reid; D J Ewing; J D Harry; H J Smith; J M Neilson; B F Clarke
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

8.  Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of beta-adrenoceptor subtypes in the dissociation between blockade and stimulation.

Authors:  M Walter; H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

9.  Studies of the agonist and antagonist activity of cicloprolol in man.

Authors:  P M McCaffrey; M Burke; J G Riddell; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients.

Authors:  B Dahlöf; M Danielson; O Andersson; T Thulin; P Ohman; C Mörlin; J Boberg; B E Karlberg; S Jern; L Hansson
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.